Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.

ABSTRACT:

Background

Liquid biopsy is a powerful tool that can enable treatment decisions for metastatic prostate cancer patients with difficult-to-biopsy tumors. However, the detection of genomic alterations via liquid biopsy is limited by the fraction (tumor fraction [TF]) of circulating tumor DNA (ctDNA) within the total cell-free DNA content. While prior work has preliminarily correlated TF with clinical features of prostate cancer, we sought to validate and provide additional resolution, such that a clinical practitioner might anticipate the probability of successful liquid biopsy profiling leveraging commonly assessed clinical and laboratory features.

Methods

A total of 813 liquid biopsy specimens were assessable, with 545 associated with a PSA prostate specific antigen measurem

SUBMITTER: Antonarakis ES 

PROVIDER: S-EPMC9314037 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature